On November 14, 2016 Corbus Pharmaceuticals Holdings, Inc. (CRBP) announced positive topline results from its Phase 2 study evaluating Resunab (“JBT-101”) for the treatment of diffuse cutaneous systemic sclerosis (“systemic sclerosis”). JBT-101 out-performed placebo in the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, reaching 33% at week 16, versus 0% for placebo. Read more >>
Skyline Medical Inc. (NASDAQ: SKLN) announces that it has received a Medical Device Establishment License to sell the STREAMWAY System and related disposables in Canada. Read more >>
For those who experience a stroke or traumatic brain injury, some are left with having to cope and adapt to having a paralyzed or weak limb. According to Cleveland Clinic, patients who have a left-brain stroke may experience paralysis on the right side of their body. Also, as stated by the National Stroke Association, as many as 9 out of 10 stroke survivors have some degree of paralysis immediately following a stroke. Myomo, a medtech company, is working to […]
The following post is from Antonette Ho, Group Operations Manager at Boston Harbor Angels.
Original post can be found here >>
Boston Harbor Angels
I recently had the privilege to attend an Angel Portfolio Workshop, hosted by the Boston Harbor Angels, one of the top angel groups in the country. Attendees were members of the Boston Harbor Angels who had diverse portfolios and a variety of experiences as angel investors. It was a lively discussion where participants shared best practices based on […]
Myomo, Inc., a commercial-stage medical robotics company whose products enable users to overcome upper extremity paralysis (www.myomo.com), announced today that it has confidentially submitted a Form 1-A with the Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock under the recently amended provisions of Regulation A pursuant to the Jumpstart Our Business Startups (JOBS) Act of 2012. The number of shares to be offered and the price range for the proposed offering […]
Cambridge, Massachusetts-based Myomo announced Friday that it is taking advantage of new SEC provisions that allow early-stage companies to raise capital without restricting it to only accredited investors
Through the Regulation A+ provision, which is an amendment to Regulation A, the Securities & Exchange Commission adopted rules that went into effect June 2015 allowing early-stage companies to raise a maximum of $50 million from the public. They are known as mini-IPOs and mark a pivotal moment given the agency accepted equity […]
Myomo, a medical robotics company whose products enable users to overcome upper extremity paralysis, has filed a Form 1-A with the SEC indicating its intent to raise money under Reg A+, a crowdfunding exemption that allows issuers to seek up to $50 million in capital. Read more >>
Myomo said today it filed with the SEC for an initial public offering, looking to register on the NYSE under the ticker symbol “MYO”.
Myomo develops and produces myoelectric orthotics for patients with neuromuscular disorders, including its flagship MyoPro line. The orthosis devices are non-invasive, powered braces used to support weak or deformed arms and hands to allow for functional activity. Read more >>
Regroup Mass Notification, the award-winning leader in emergency and day-to-day communication technology, today announced joint alliance with Alvarez Associates, an industry leader in workplace violence prevention. Read more >>